Skip to main content
Erschienen in:

01.11.2005 | AUO

Systemische Therapie des fortgeschrittenen Urothelkarzinoms

verfasst von: Dr. J. Lehmann, M. Retz, M. Stöckle

Erschienen in: Die Onkologie | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Über die Wirksamkeit systemischer Chemotherapeutika zur Behandlung des Urothelkarzinoms wird seit mehr als 30 Jahren berichtet. Mit der Kombination verschiedener Substanzen wurde ab Mitte der 80er Jahre eine potenzielle Heilbarkeit auch fortgeschrittener Erkrankungsstadien in dieser Tumorentität postuliert, was seither in eine Serie von Phase-III-Studien zur systemischen Kombinationstherapie in dieser Entität mündete. Dieser Beitrag stellt die Ergebnisse aus den Indikationsbereichen der palliativen systemischen Chemotherapie des fortgeschrittenen metastasierten Urothelkarzinoms sowie der neoadjuvanten und adjuvanten systemischen Kombinationschemotherapie des muskelinvasiven bzw. lokal fortgeschrittenen resektablen Harnblasenkarzinoms zusammen.
Literatur
1.
Zurück zum Zitat Abol-Enein H, El Makresh M, El Baz M, Ghoneim M (1997) Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomized study. Br J Urol 80:49PubMed Abol-Enein H, El Makresh M, El Baz M, Ghoneim M (1997) Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomized study. Br J Urol 80:49PubMed
2.
Zurück zum Zitat Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48:189–199CrossRefPubMed Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48:189–199CrossRefPubMed
3.
Zurück zum Zitat Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48:202–205CrossRefPubMed Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48:202–205CrossRefPubMed
4.
Zurück zum Zitat Bajorin DF, Dodd PM, Mazumdar M et al. (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181PubMed Bajorin DF, Dodd PM, Mazumdar M et al. (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181PubMed
5.
Zurück zum Zitat Bamias A, Aravantinos G, Deliveliotis C et al. (2004) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:220–228CrossRefPubMed Bamias A, Aravantinos G, Deliveliotis C et al. (2004) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:220–228CrossRefPubMed
6.
Zurück zum Zitat Bannowsky A, Wefer B, Naumann M, Hamann M, Hautmann S, Jünemann KP (2005) Second-line-Polychemotherapie beim metastasierten Urothelkarzinom des Nierenbeckens. Andauernde partielle Remission nach 18 Kursen Gemcitabin/Paclitaxel trotz 24 Kursen Gemcitabin/Cisplatin im „stable disease“. Urologe A 44:915–917CrossRefPubMed Bannowsky A, Wefer B, Naumann M, Hamann M, Hautmann S, Jünemann KP (2005) Second-line-Polychemotherapie beim metastasierten Urothelkarzinom des Nierenbeckens. Andauernde partielle Remission nach 18 Kursen Gemcitabin/Paclitaxel trotz 24 Kursen Gemcitabin/Cisplatin im „stable disease“. Urologe A 44:915–917CrossRefPubMed
7.
Zurück zum Zitat Bassi P, Pappagallo GL, Sperandio P et al. (1999) Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: Results of a multicenter phase III trial. J Urol 161:264CrossRef Bassi P, Pappagallo GL, Sperandio P et al. (1999) Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: Results of a multicenter phase III trial. J Urol 161:264CrossRef
8.
Zurück zum Zitat Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, Baselga J (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751–757CrossRefPubMed Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, Baselga J (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751–757CrossRefPubMed
9.
Zurück zum Zitat Bellmunt J, Guillem V, Paz-Ares L et al. (2000) Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18:3247–3255PubMed Bellmunt J, Guillem V, Paz-Ares L et al. (2000) Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18:3247–3255PubMed
10.
Zurück zum Zitat Carteni G, Dogliotti L, Crucitta E et al. (2003) Phase II randomised trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 22:384 Carteni G, Dogliotti L, Crucitta E et al. (2003) Phase II randomised trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 22:384
11.
Zurück zum Zitat Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957–1962PubMed Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957–1962PubMed
12.
Zurück zum Zitat Dreicer R, Manola J, Roth B, See W, Kuross S, Edelman MJ, Wilding G (2003) ECOG 4897: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Proc Am Soc Clin Oncol 22:384 Dreicer R, Manola J, Roth B, See W, Kuross S, Edelman MJ, Wilding G (2003) ECOG 4897: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Proc Am Soc Clin Oncol 22:384
13.
Zurück zum Zitat Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495–499CrossRefPubMed Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495–499CrossRefPubMed
14.
Zurück zum Zitat Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22:777–784CrossRefPubMed Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22:777–784CrossRefPubMed
15.
Zurück zum Zitat Grossman HB, Natale RB, Tangen CM et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866CrossRefPubMed Grossman HB, Natale RB, Tangen CM et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866CrossRefPubMed
16.
Zurück zum Zitat Hussain M, Petrylak DP, Dunn R et al. (2005) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced HER2-positive urothelial carcinoma: Results of a Multi-Center Phase II NCI Trial. J Clin Oncol 23:379 (abstract 4507) Hussain M, Petrylak DP, Dunn R et al. (2005) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced HER2-positive urothelial carcinoma: Results of a Multi-Center Phase II NCI Trial. J Clin Oncol 23:379 (abstract 4507)
17.
Zurück zum Zitat International collaboration of trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540CrossRefPubMed International collaboration of trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540CrossRefPubMed
18.
Zurück zum Zitat Lehmann J, Retz M, Wiemers C et al. (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23:4963–4974CrossRefPubMed Lehmann J, Retz M, Wiemers C et al. (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23:4963–4974CrossRefPubMed
19.
Zurück zum Zitat Lehmann J, Stöckle M (2005) Therapie des systemischen Rezidivtumors beim Urothelkarzinom. Urologe A 44:369–374CrossRefPubMed Lehmann J, Stöckle M (2005) Therapie des systemischen Rezidivtumors beim Urothelkarzinom. Urologe A 44:369–374CrossRefPubMed
20.
Zurück zum Zitat Lippert C, Koser M (2001) Gemcitabine and cisplatinum in a 21-day schedule in the first-line treatment of locally advanced or metastatic transitional cell carcinoma: preliminary results of a phase II study. Proc Am Soc Clin Oncol 20:(abstract 783) Lippert C, Koser M (2001) Gemcitabine and cisplatinum in a 21-day schedule in the first-line treatment of locally advanced or metastatic transitional cell carcinoma: preliminary results of a phase II study. Proc Am Soc Clin Oncol 20:(abstract 783)
21.
Zurück zum Zitat Loehrer PJ, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073PubMed Loehrer PJ, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073PubMed
22.
Zurück zum Zitat Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055PubMed Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055PubMed
23.
Zurück zum Zitat Logothetis CJ, Johnson DE, Chong C et al. (1988) Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6:1590–1596PubMed Logothetis CJ, Johnson DE, Chong C et al. (1988) Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6:1590–1596PubMed
24.
Zurück zum Zitat Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155:1903–1906CrossRefPubMed Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155:1903–1906CrossRefPubMed
25.
Zurück zum Zitat Martinez-Pineiro JA, Gonzalez MM, Arocena F et al. (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153:964–973CrossRefPubMed Martinez-Pineiro JA, Gonzalez MM, Arocena F et al. (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153:964–973CrossRefPubMed
26.
Zurück zum Zitat Mottet-Auselo N, Bons-Rosset F, Costa P, Louis JF, Navratil H (1993) Carboplatin and urothelial tumors. Oncology 50 [Suppl 2]:28–36 Mottet-Auselo N, Bons-Rosset F, Costa P, Louis JF, Navratil H (1993) Carboplatin and urothelial tumors. Oncology 50 [Suppl 2]:28–36
27.
Zurück zum Zitat Otto T, Börgermann C, Krege S, Rübben H (2001) Adjuvant chemotherapy in locally advanced bladder cancer [pT3/pT4a,pN1–2,M0] - a phase III study. Eur Urol 39 [Suppl 2]:147 Otto T, Börgermann C, Krege S, Rübben H (2001) Adjuvant chemotherapy in locally advanced bladder cancer [pT3/pT4a,pN1–2,M0] - a phase III study. Eur Urol 39 [Suppl 2]:147
28.
Zurück zum Zitat Otto T, Krege S, Suhr J, Rübben H (2001) Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57:55–59CrossRefPubMed Otto T, Krege S, Suhr J, Rübben H (2001) Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57:55–59CrossRefPubMed
29.
Zurück zum Zitat Paz-Ares L, Tabernero J, Moyano A et al. (1998) Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Ann Oncol 9:abstract 292 Paz-Ares L, Tabernero J, Moyano A et al. (1998) Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Ann Oncol 9:abstract 292
30.
Zurück zum Zitat Pegram MD, Slamon DJ (1999) Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26:89–95 Pegram MD, Slamon DJ (1999) Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26:89–95
31.
Zurück zum Zitat Petrylak DP, Faulkner JR, van Veldhuizen PJ, Mansukhani M, Crawford ED (2003) Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 22:403 Petrylak DP, Faulkner JR, van Veldhuizen PJ, Mansukhani M, Crawford ED (2003) Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 22:403
32.
Zurück zum Zitat Pianezza O, Meneguelo M, Merlo F, Feroldi L, Parma P, Fandella A, Martini E, Saredi G, Lovisolo JA, Bono AV (2003) Adjuvant chemotherapy in locally advanced bladder cancer: Long-term follow-up of a multicenter study. J Urol 169 [Suppl]:337 Pianezza O, Meneguelo M, Merlo F, Feroldi L, Parma P, Fandella A, Martini E, Saredi G, Lovisolo JA, Bono AV (2003) Adjuvant chemotherapy in locally advanced bladder cancer: Long-term follow-up of a multicenter study. J Urol 169 [Suppl]:337
33.
Zurück zum Zitat Raghavan D (2003) Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97:2083–2089CrossRefPubMed Raghavan D (2003) Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97:2083–2089CrossRefPubMed
34.
Zurück zum Zitat Redman BG, Smith DC, Flaherty L, Du W, Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844–1848PubMed Redman BG, Smith DC, Flaherty L, Du W, Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844–1848PubMed
35.
Zurück zum Zitat Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB (2003) An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169:110–115CrossRefPubMed Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB (2003) An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169:110–115CrossRefPubMed
36.
Zurück zum Zitat Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump D (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564–2569PubMed Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump D (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564–2569PubMed
37.
Zurück zum Zitat Sengelov L, von der Maase H, Lundbeck F et al. (2002) Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 41:447–456CrossRefPubMed Sengelov L, von der Maase H, Lundbeck F et al. (2002) Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 41:447–456CrossRefPubMed
38.
Zurück zum Zitat Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmstrom PU (2002) Neoadjuvant Cisplatin-methotrexate chemotherapy for invasive bladder cancer — nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425CrossRefPubMed Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmstrom PU (2002) Neoadjuvant Cisplatin-methotrexate chemotherapy for invasive bladder cancer — nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425CrossRefPubMed
39.
Zurück zum Zitat Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ (2002) Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20:1361–1367CrossRefPubMed Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ (2002) Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20:1361–1367CrossRefPubMed
40.
Zurück zum Zitat Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE (2004) Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 171:145–148CrossRefPubMed Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE (2004) Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 171:145–148CrossRefPubMed
41.
Zurück zum Zitat Skinner DG, Daniels JR, Russell CA et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464PubMed Skinner DG, Daniels JR, Russell CA et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464PubMed
42.
Zurück zum Zitat Small EJ, Lew D, Redman BG et al. (2000) Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial end point. J Clin Oncol 18:2537–2544PubMed Small EJ, Lew D, Redman BG et al. (2000) Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial end point. J Clin Oncol 18:2537–2544PubMed
43.
Zurück zum Zitat Soto Parra H, Cavina R, Latteri F et al. (2002) Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 13:1080–1086CrossRefPubMed Soto Parra H, Cavina R, Latteri F et al. (2002) Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 13:1080–1086CrossRefPubMed
44.
Zurück zum Zitat Sridhar S, Stadler W, Le L et al. (2005) Phase 2 study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital Phase II consortium. J Clin Oncol 23:422 (abstract 4677)CrossRefPubMed Sridhar S, Stadler W, Le L et al. (2005) Phase 2 study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital Phase II consortium. J Clin Oncol 23:422 (abstract 4677)CrossRefPubMed
45.
Zurück zum Zitat Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170:35–41CrossRefPubMed Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170:35–41CrossRefPubMed
46.
Zurück zum Zitat Sternberg C, de Mulder PH, Schornagel JH et al. (2005) Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. J Clin Oncol 23:384 (abstract 4528) Sternberg C, de Mulder PH, Schornagel JH et al. (2005) Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. J Clin Oncol 23:384 (abstract 4528)
47.
Zurück zum Zitat Sternberg CN, de Mulder PH, Schornagel JH et al. (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646PubMed Sternberg CN, de Mulder PH, Schornagel JH et al. (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646PubMed
48.
Zurück zum Zitat Sternberg CN, Yagoda A, Scher HI et al. (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407PubMed Sternberg CN, Yagoda A, Scher HI et al. (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407PubMed
49.
Zurück zum Zitat Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458PubMed Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458PubMed
50.
Zurück zum Zitat Stöckle M, Meyenburg W, Wellek S et al. (1992) Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148:302–306PubMed Stöckle M, Meyenburg W, Wellek S et al. (1992) Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148:302–306PubMed
51.
Zurück zum Zitat Studer UE, Bacchi M, Biedermann C et al. (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152:81–84PubMed Studer UE, Bacchi M, Biedermann C et al. (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152:81–84PubMed
52.
Zurück zum Zitat Sweeney C, Roth B, Kaufman D, Nicol S (2003) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the bladder. Proc Am Soc Clin Oncol 22:411 Sweeney C, Roth B, Kaufman D, Nicol S (2003) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the bladder. Proc Am Soc Clin Oncol 22:411
53.
Zurück zum Zitat Sweeney P, Millikan R, Donat M et al. (2003) Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169:2113–2117CrossRefPubMed Sweeney P, Millikan R, Donat M et al. (2003) Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169:2113–2117CrossRefPubMed
54.
Zurück zum Zitat Sylvester R, Sternberg C (2000) The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 11:851–856CrossRefPubMed Sylvester R, Sternberg C (2000) The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 11:851–856CrossRefPubMed
55.
Zurück zum Zitat Takata R, Katagiri T, Kanehira M et al. (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11:2625–2636CrossRefPubMed Takata R, Katagiri T, Kanehira M et al. (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11:2625–2636CrossRefPubMed
56.
Zurück zum Zitat Vaughn DJ, Malkowicz SB, Zoltick B et al. (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16:255–260PubMed Vaughn DJ, Malkowicz SB, Zoltick B et al. (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16:255–260PubMed
57.
Zurück zum Zitat von der Maase H, Lehmann J, Gravis G, Joensuu H, Bihn B, Geertsen P, Gough J, Chen Z (2005) A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinoma of the urothelium. J Clin Oncol 23:400 (abstract 4592) von der Maase H, Lehmann J, Gravis G, Joensuu H, Bihn B, Geertsen P, Gough J, Chen Z (2005) A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinoma of the urothelium. J Clin Oncol 23:400 (abstract 4592)
58.
Zurück zum Zitat von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077PubMed von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077PubMed
59.
Zurück zum Zitat von der Maase H, Sengelov L, Roberts JT et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608CrossRefPubMed von der Maase H, Sengelov L, Roberts JT et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608CrossRefPubMed
60.
Zurück zum Zitat Wallace DM, Raghavan D, Kelly KA et al. (1991) Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67:608–615PubMed Wallace DM, Raghavan D, Kelly KA et al. (1991) Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67:608–615PubMed
61.
Zurück zum Zitat Wülfing C, Machiels J, Richel D et al. (2005) A single arm, multicenter, open label, ph II study of lapatinib as second-line treatment of pts with locally advanced/metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol 23:401 s (abstract 4594) Wülfing C, Machiels J, Richel D et al. (2005) A single arm, multicenter, open label, ph II study of lapatinib as second-line treatment of pts with locally advanced/metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol 23:401 s (abstract 4594)
62.
Zurück zum Zitat Zai S, Castagneto B, Marenco D, Botta M (2003) Gemcitabine monochemotherapy in elderly patients with advanced bladder carcinoma: Response to treatment and its correlation with the comprehensive geriatric assessment. Proc Am Soc Clin Oncol 22:425 Zai S, Castagneto B, Marenco D, Botta M (2003) Gemcitabine monochemotherapy in elderly patients with advanced bladder carcinoma: Response to treatment and its correlation with the comprehensive geriatric assessment. Proc Am Soc Clin Oncol 22:425
63.
Zurück zum Zitat Zielinski CC, Schnack B, Grbovic M et al. (1998) Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 78:370–374PubMed Zielinski CC, Schnack B, Grbovic M et al. (1998) Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 78:370–374PubMed
Metadaten
Titel
Systemische Therapie des fortgeschrittenen Urothelkarzinoms
verfasst von
Dr. J. Lehmann
M. Retz
M. Stöckle
Publikationsdatum
01.11.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 11/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0970-x

Weitere Artikel der Ausgabe 11/2005

Der Onkologe 11/2005 Zur Ausgabe

Weiterbildung · Zertifizierte Fortbildung

Perkutane Strahlentherapie der Knochenmetastasen

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.